Considered and approve the unaudited financial results for the quarter ended June 30, 2025 along with limited review report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.2 pts less than Nifty Microcap 250 and 15.2 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Genomic Valley Biotech Ltd approved the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26) along with an unqualified limited review report from statutory auditor Andros & Co. The company reported a Profit After Tax of about Rs. 2.47 lakh for Q1 FY26, a sharp drop from roughly Rs. 12.76 lakh in the same quarter last year (a YoY decline of around 80%). The preceding quarter (Q4 FY25) had actually ended in a loss of about Rs. 8.35 lakh, so the company returned to marginal profitability in Q1 FY26. The Board also appointed M/s SBR & Co. LLP as Secretarial Auditor for FY 2025-30 and Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2025-26. Additionally, Mr. Yogesh Agrawal was re-appointed as Chairman and Managing Director for another five-year term starting September 7, 2025.
The steep YoY fall in profit is a concern for shareholders, though absolute earnings remain very small. Continuity at the top with the CMD re-appointment and a clean audit opinion provide some comfort, but investors should watch for whether revenue and margins recover in coming quarters.